NASDAQ : AKTS
Aktis Oncology, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 15.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 886.02M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Aktis Oncology, Inc. (AKTS) reported revenue of 10.06M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | 10.06M | 6.50M | 1.49M | ||
| Cost of Revenue | 78.28M | 67.45M | 40.95M | 25.92M | |
| Gross Profit | -68.22M | -60.95M | -39.47M | -25.92M | |
| Selling, General & Admin | 18.97M | 13.73M | 12.58M | 8.88M | 5.46M |
| Research & Development | 14.30M | ||||
| Operating Expenses | 18.97M | 13.73M | 12.58M | 8.88M | 19.76M |
| Operating Income | -87.18M | -74.68M | -52.05M | -34.79M | -19.76M |
| Interest & Investment Income | 14.08M | 11.01M | 8.10M | 5.38M | 1.65M |
| Other Non Operating Income (Expenses) | -36.00K | -56.00K | -33.00K | 776.00K | 188.00K |
| Pretax Income | -73.14M | -63.73M | -43.98M | -28.64M | -17.93M |
| Net Income | -73.14M | -63.73M | -43.98M | -28.64M | -17.93M |
| Net Income to Common | -73.14M | -63.73M | -43.98M | -28.64M | -17.93M |
| Shares Outstanding (Basic) | 26.40M | 813.52K | 704.16K | 615.21K | 517.40K |
| Shares Outstanding (Diluted) | 26.40M | 813.52K | 704.16K | 615.21K | 517.40K |
| EPS (Basic) | -2.77 | -78.34 | -62.46 | -46.55 | -34.65 |
| EPS (Diluted) | -2.77 | -78.34 | -62.46 | -46.55 | -34.65 |
| Free Cash Flow | -84.57M | -73.71M | 11.90M | -33.77M | -20.43M |
| Free Cash Flow Per Share | -3.20 | -90.61 | 16.90 | -54.89 | -39.49 |
| Operating Margin | -866.63% | -1,149.52% | -3,500.34% | ||
| Profit Margin | -727.04% | -980.93% | -2,957.63% | ||
| Free Cash Flow Margin | -840.62% | -1,134.54% | 800.27% | ||
| EBITDA | -84.36M | -72.36M | -50.48M | -33.67M | -19.32M |
| D&A For EBITDA | 2.82M | 2.33M | 1.57M | 1.12M | 445.00K |
| EBIT | -87.18M | -74.68M | -52.05M | -34.79M | -19.76M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 82.49M | 37.78M | 37.16M | 29.51M | 128.60M |
| Short-Term Investments | 434.83M | 189.00M | 260.01M | 68.35M | |
| Cash & Short-Term Investments | 517.32M | 226.79M | 297.17M | 97.86M | 128.60M |
| Other Receivables | 2.30M | 1.10M | 1.10M | 300.00K | |
| Receivables | 2.30M | 1.10M | 1.10M | 300.00K | |
| Prepaid Expenses | 4.92M | 2.42M | 2.58M | 2.04M | 3.88M |
| Total Current Assets | 524.54M | 230.31M | 300.85M | 100.20M | 132.48M |
| Property, Plant & Equipment | 28.20M | 27.25M | 20.87M | 20.92M | 4.87M |
| Other Long-Term Assets | 4.86M | 7.33M | 4.46M | 1.23M | 976.00K |
| Total Assets | 557.60M | 264.88M | 326.18M | 122.36M | 138.32M |
| Accounts Payable | 2.53M | 1.74M | 1.92M | 957.00K | 490.00K |
| Accrued Expenses | 10.78M | 9.52M | 6.33M | 3.75M | 3.93M |
| Current Portion of Leases | 1.48M | 1.31M | 1.30M | 1.53M | 854.00K |
| Current Unearned Revenue | 17.34M | 18.66M | 9.28M | ||
| Total Current Liabilities | 32.13M | 31.24M | 18.82M | 6.24M | 5.28M |
| Long-Term Leases | 9.76M | 10.23M | 10.71M | 11.87M | 921.00K |
| Long-Term Unearned Revenue | 30.87M | 36.16M | 51.04M | ||
| Other Long-Term Liabilities | 500.00K | 1.31M | |||
| Total Liabilities | 72.76M | 77.62M | 80.58M | 18.61M | 7.50M |
| Additional Paid-In Capital | 684.61M | 10.37M | 4.91M | 2.46M | 982.00K |
| Retained Earnings | -199.03M | -156.56M | -92.83M | -48.85M | -20.21M |
| Comprehensive Income & Other | -745.00K | 42.00K | 124.00K | 82.00K | |
| Total Common Equity | 484.84M | -146.15M | -87.80M | -46.31M | -19.23M |
| Shareholders' Equity | 484.84M | 187.26M | 245.61M | 103.74M | 130.82M |
| Total Liabilities & Equity | 557.60M | 264.88M | 326.18M | 122.36M | 138.32M |
| Total Debt | 11.24M | 11.55M | 12.01M | 13.40M | 1.77M |
| Net Cash (Debt) | 506.08M | 215.24M | 285.16M | 84.46M | 126.82M |
| Net Cash Per Share | 19.17 | 264.58 | 404.96 | 137.29 | 245.11 |
| Filing Date Shares Outstanding | 55.62M | 55.28M | 781.00K | 649.74K | 517.40K |
| Total Common Shares Outstanding | 55.32M | 915.26K | 781.00K | 649.74K | 517.40K |
| Working Capital | 492.41M | 199.07M | 282.03M | 93.97M | 127.21M |
| Book Value Per Share | 8.76 | -159.68 | -112.42 | -71.27 | -37.17 |
| Tangible Book Value | 484.84M | -146.15M | -87.80M | -46.31M | -19.23M |
| Tangible Book Value Per Share | 8.76 | -159.68 | -112.42 | -71.27 | -37.17 |
| Machinery | 13.79M | 12.75M | 8.81M | 6.40M | 2.74M |
| Construction In Progress | 3.37M | 7.01M | 1.33M | 395.00K | 557.00K |
| Leasehold Improvements | 5.57M | 167.00K | 167.00K | 167.00K | 167.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -73.14M | -63.73M | -43.98M | -28.64M | -17.93M |
| Depreciation & Amortization | 2.82M | 2.33M | 1.57M | 1.12M | 445.00K |
| Loss (Gain) From Sale of Investments | -3.02M | -4.62M | -4.08M | -3.15M | |
| Stock-Based Compensation | 8.62M | 5.13M | 2.26M | 1.48M | 698.00K |
| Other Operating Activities | 8.00K | -800.00K | -200.00K | ||
| Change in Accounts Payable | 732.00K | -44.00K | 360.00K | 659.00K | -1.00K |
| Change in Unearned Revenue | -9.06M | -5.50M | 58.51M | ||
| Change in Other Net Operating Assets | -2.25M | 2.31M | 107.00K | -674.00K | -1.14M |
| Operating Cash Flow | -75.29M | -64.13M | 14.76M | -30.00M | -18.12M |
| Capital Expenditures | -9.27M | -9.58M | -2.86M | -3.76M | -2.31M |
| Sale of Property, Plant & Equipment | 57.00K | ||||
| Investment in Securities | -280.12M | 75.55M | -187.54M | -65.12M | |
| Investing Cash Flow | -289.39M | 65.96M | -190.40M | -68.83M | -2.31M |
| Issuance of Common Stock | 340.25M | 336.00K | 179.00K | ||
| Other Financing Activities | -3.29M | -1.55M | -1.90M | -151.00K | |
| Financing Cash Flow | 336.96M | -1.21M | 183.28M | 119.98M | |
| Net Cash Flow | -27.72M | 625.00K | 7.65M | -98.83M | 99.55M |
| Free Cash Flow | -84.57M | -73.71M | 11.90M | -33.77M | -20.43M |
| Free Cash Flow Margin | -840.62% | -1,134.54% | 800.27% | ||
| Free Cash Flow Per Share | -3.20 | -90.61 | 16.90 | -54.89 | -39.49 |
| Levered Free Cash Flow | -36.24M | -20.08M | -21.08M | ||
| Unlevered Free Cash Flow | -36.24M | -20.08M | -21.08M | ||
| Change in Working Capital | -10.58M | -3.23M | 58.98M | -15.00K | -1.14M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 886.02M | ||||
| Enterprise Value | 379.94M | ||||
| Debt / Equity Ratio | 0.02 | 0.06 | 0.05 | 0.13 | 0.01 |
| Debt / FCF Ratio | 1.01 | ||||
| Net Debt / Equity Ratio | -1.04 | -1.15 | -1.16 | -0.81 | -0.97 |
| Net Debt / EBITDA Ratio | 6.00 | 2.98 | 5.65 | 2.51 | 6.57 |
| Net Debt / FCF Ratio | 5.98 | 2.92 | -23.96 | 2.50 | 6.21 |
| Asset Turnover | 0.02 | 0.01 | |||
| Quick Ratio | 16.17 | 7.30 | 15.85 | 15.74 | 24.38 |
| Current Ratio | 16.33 | 7.37 | 15.98 | 16.07 | 25.11 |
| Return on Equity (ROE) | -29.45% | -25.18% | -24.42% | ||
| Return on Assets (ROA) | -15.79% | -14.51% | -16.68% | ||
| Return on Capital Employed (ROCE) | -16.60% | -32.00% | -16.90% | -30.00% | -14.90% |
| Buyback Yield / Dilution | -3,649.41% | -15.53% | -14.46% | -18.90% |